Article | February 3, 2025

Advancements In GLP-1 Analog Formulation Development: Overcoming Challenges In Oral Delivery

Weight Loss_GettyImages-2123088969

More than half the global population is expected to be either overweight or obese by 2035. As a chronic condition, obesity has grown into a major therapeutic segment, as well as a key contributor to incidence of metabolic disorders.

Human glucagon-like peptide 1 (GLP-1) analogs, also called incretin mimetics, have emerged as a promising obesity treatment option. Additionally, oral GLP-1 formulations represent a groundbreaking advance in obesity treatment, offering improved patient comfort and adherence while expanding the therapeutic market.

An extended half-life and bioavailability (BA) are critical to a GPL-1 analog’s effectiveness. Enhancing these factors helps the drug achieve required bioavailability and remain active for longer periods of time. A myriad of protein engineering and formulation/drug delivery systems can be leveraged to optimize oral GLP-1’s stability, BA, and half-life.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Life Science Leader